In the hypoxic tumor microenvironment, MT2A supports cancer cell survival by neutralizing oxidative stress and contributing to chemotherapy resistance (Krizkova et al., 2018; Moffatt & Denizeau, 1997). This evidence concerns the gene MT2A and neoplasm.